New Amsterdam Sciences

Executive Summary

New Amsterdam Sciences is a private biopharmaceutical company focused on developing novel small molecule therapies for oxidative stress (ROS)-driven inflammatory conditions. Founded in 2018 and headquartered in New York, the company targets diseases such as rheumatoid arthritis, infectious diseases, and CNS disorders, addressing a significant unmet need in persistent inflammation. By targeting reactive oxygen species, New Amsterdam aims to provide safer and more effective alternatives to current anti-inflammatory treatments. The company's approach leverages the central role of oxidative stress in chronic inflammation, potentially offering broad applicability across multiple therapeutic areas. While still in early stages without disclosed pipeline details, New Amsterdam represents a preclinical-stage biotech with a compelling scientific rationale and a clear focus on high-value indications.

Upcoming Catalysts (preview)

• Q2 2027Lead IND Filing for Rheumatoid Arthritis Candidate30% success
• Q4 2026Preclinical Proof-of-Concept Data in CNS Model40% success
• TBDSeries A or B Financing Announcement50% success